BioSpace News Archive

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its first quarter 2021 financial and operating results on Thursday, May 6, 2021 , before the U.S. financial markets open.

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will participate in the 20th Annual Needham Virtual Healthcare Conference, a fully virtual management access conference, taking place April 12-15. President and Chief Executive Officer, Mark Foley, is scheduled to participate in a fireside chat on Tuesday, Ap

QIAseq DIRECT SARS-CoV-2 Kit halves both library preparation times and plasticware use Kit supports analysis of over 6,000 samples simultaneously on highest-throughput sequencers Integrates with QIAGEN Digital Insights cloud solutions to support variant detection and reporting including clade and lineage annotations across sequencing platforms

Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, today announced that the Company intends to offer and sell, subject to market and other conditions, $50.0 million of its common stock in an underwritten public offering. Homology expects to grant the underwriter a 30-day option to purchase up to an additional $7.5 million of its common stock

FDA Fast Track Designation has been granted to DAV132 for the prevention of Clostridioides difficile infection, a life-threatening condition with persistent unmet medical need, especially in cancer patients

CM Life Sciences III Inc. announced that it priced its initial public offering of 48,000,000 units at $10.00 per unit.

TransMedics Group, Inc. announced that after the review of TransMedics’ clinical evidence from the OCS Heart EXPAND trial, the associated Continued Access Protocol results, as well as the OCS Heart PROCEED II trial, the Circulatory Systems Device Advisory Panel convened by the U.S. Food and Drug Administration has issued a favorable vote in support of approval of the OCS Heart System to the FDA’s Office of Health Technology 2.

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today congratulates uniQure N.V. on the early completion of patient enrollment in the first dose cohort of a randomized, double-blinded, Phase I/II clinical trial of AMT-130 being conducted in the United States for the treatment of early-stage Huntington’s disease.

FibroGen, Inc. provided clarification of certain prior disclosures of U.S. primary cardiovascular safety analyses from the roxadustat Phase 3 program for the treatment of anemia of chronic kidney disease.

Bio-Techne Corporation (NASDAQ: TECH) today announced it has completed the acquisition of Asuragen, Inc. The transaction included initial consideration of $215 million in cash plus contingent consideration of up to $105 million upon the achievement of certain future milestones.